| 词条 | DS-1 (drug) |
| 释义 |
| drug_name = DS-1 | verifiedrevid = 451225367 | IUPAC_name = 4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide | image = DS-1.svg | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | excretion = | IUPHAR_ligand = 4183 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 372497-52-4 | ATC_prefix = | ATC_suffix = | PubChem = 979735 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 849261 | C=18 | H=10 | Br=2 | Cl=1 | N=3 | O=1 | S=1 | molecular_weight = 511.617 g/mol | smiles = s4cccc4-c2nc1c(Br)cc(Br)cn1c2NC(=O)c(cc3)ccc3Cl }}DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1] See also
References1. ^{{cite journal | last1 = Wafford | first1 = KA | last2 = Van Niel | first2 = MB | last3 = Ma | first3 = QP | last4 = Horridge | first4 = E | last5 = Herd | first5 = MB | last6 = Peden | first6 = DR | last7 = Belelli | first7 = D | last8 = Lambert | first8 = JJ | title = Novel compounds selectively enhance delta subunit containing GABA a receptors and increase tonic currents in thalamus | journal = Neuropharmacology | volume = 56 | issue = 1 | pages = 182–9 | year = 2009 | pmid = 18762200 | doi = 10.1016/j.neuropharm.2008.08.004 }} {{GABAAR PAMs}}{{sedative-stub}} 6 : Benzamides|Chloroarenes|GABAA receptor positive allosteric modulators|Imidazopyridines|Organobromides|Thiophenes |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。